| 0 (0%) | 11-30 08:01 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 78.16 | 1-year : | 91.29 |
| Resists | First : | 66.91 | Second : | 78.16 |
| Pivot price | 58.65 |
|||
| Supports | First : | 58 | Second : | 52.5 |
| MAs | MA(5) : | 60.83 |
MA(20) : | 58.5 |
| MA(100) : | 44.46 |
MA(250) : | 25.53 |
|
| MACD | MACD : | 1.2 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 89 |
D(3) : | 75.2 |
| RSI | RSI(14): 60.4  |
|||
| 52-week | High : | 66.91 | Low : | 0.66 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NKTR ] has closed below upper band by 0.8%. Bollinger Bands are 5.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 66.6 - 66.87 | 66.87 - 67.15 |
| Low: | 59.74 - 60 | 60 - 60.26 |
| Close: | 65.23 - 65.72 | 65.72 - 66.21 |
Wed, 26 Nov 2025
Citigroup Initiates Coverage on NKTR with 'Buy' Rating | NKTR St - GuruFocus
Wed, 26 Nov 2025
Citigroup Initiates Coverage of Nektar Therapeutics (NKTR) with Buy Recommendation - Nasdaq
Wed, 26 Nov 2025
New Analyst Forecast: $NKTR Given $102 Price Target - Quiver Quantitative
Tue, 25 Nov 2025
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - simplywall.st
Tue, 25 Nov 2025
How Investors May Respond To Nektar Therapeutics (NKTR) Clinical Progress and Leadership Transition - Sahm
Wed, 12 Nov 2025
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 20 (M) |
| Shares Float | 19 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 72.1 (%) |
| Shares Short | 1,470 (K) |
| Shares Short P.Month | 1,970 (K) |
| EPS | -9.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.32 |
| Profit Margin | -192.9 % |
| Operating Margin | -267.5 % |
| Return on Assets (ttm) | -28 % |
| Return on Equity (ttm) | -180.3 % |
| Qtrly Rev. Growth | -51.1 % |
| Gross Profit (p.s.) | 2.68 |
| Sales Per Share | 3.07 |
| EBITDA (p.s.) | -6.65 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -190 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -6.64 |
| PEG Ratio | 0 |
| Price to Book value | 15.06 |
| Price to Sales | 21.18 |
| Price to Cash Flow | -7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|